Ziltivekimab IL-6 ligand cardiovascular risk CANTOS follow-up

Indicated For

Cardiovascular disease, Chronic kidney disease, Heart failure

About This Medication

# Novo Nordisk Patient Assistance Program for Ziltivekimab: Patient Guide ## About This Program The Novo Nordisk Patient Assistance Program (PAP) provides prescription medications at no cost to patients who qualify based on financial need and other eligibility criteria. This guide explains how to access ziltivekimab, an investigational medication being developed by Novo Nordisk, through this program. ## Important Note About Ziltivekimab Ziltivekimab is currently an investigational drug being studied in clinical trials and is not yet approved by the FDA for general use outside of research studies. It is being developed as a potential treatment for cardiovascular conditions, including heart disease and heart failure with inflammation. Availability through the Patient Assistance Program may be limited to patients enrolled in approved clinical trials or those with specific medical circumstances. Contact Novo Nordisk directly at 1-800-488-5908 to determine current availability and eligibility. ## Who Can Qualify To be eligible for the Novo Nordisk Patient Assistance Program, you must meet the following criteria: - Be a U.S. resident or legal alien - Have a valid prescription from a licensed healthcare provider - Meet the program's financial eligibility requirements - Not be eligible for Medicaid or Medicare Low Income Subsidy (LIS), or have submitted a denial letter from these programs - Meet any additional program-specific requirements ## Income Eligibility While specific income thresholds for ziltivekimab are not detailed in current program materials, the Novo Nordisk PAP generally considers household income relative to the Federal Poverty Level. Other Novo Nordisk assistance programs use thresholds ranging from 200% to 300% of the Federal Poverty Level, depending on the specific program and insurance status. To determine your eligibility based on income, you will need to provide proof of income during the application process. Contact the program directly for current income guidelines specific to ziltivekimab. ## Insurance Requirements The program is available to: - **Uninsured patients** with no prescription drug coverage - **Underinsured patients** with limited coverage - **Medicare Part D patients** (no longer required to spend $1,000 out-of-pocket first) - **Patients with private or commercial insurance** (eligibility varies) If you are eligible for Medicaid or Medicare LIS, you must submit a copy of your denial letter with your application. ## How to Apply **Step 1: Submit Your Application** Visit the Novo Nordisk NovoCare website to begin your application. You will need your healthcare provider's email address, as they must complete their portion of the application. Your provider will receive a secure link via email to verify your medical need and prescription. **Step 2: Provide Required Documentation** During the application process, you may be asked to provide: - Proof of income (recent tax return, pay stubs, or benefit statements) - Government-issued ID - Medicaid or Medicare LIS denial letter (if applicable) - Any other documentation requested by the program **Step 3: Application Processing** If your application is submitted with all required information and supporting documentation completed, it will be processed within 2 business days. Incomplete applications may experience delays. **Step 4: Approval and Delivery** If approved, you will receive a letter in the mail. If you opted for automated alerts during your application, you will also receive a phone or text message notification. Approved patients will be contacted by Neovance Specialty Pharmacy at 1-800-488-5908 to schedule home delivery of your medication. ## Timeline and Delivery - **Processing time:** 2 business days (with complete information) - **Delivery method:** Home delivery through Neovance Specialty Pharmacy - **Supply:** Up to a 120-day supply per shipment - **Refills:** Neovance will contact you by phone or text to coordinate refill shipments - **Program validity:** For uninsured patients, approval is valid for 12 months. For Medicare Part D patients, approval is valid for the benefit year only. ## What If Your Application Is Denied? If your application is denied, contact Novo Nordisk or your healthcare provider to understand the reason. Common reasons for denial include: - Income exceeding program limits - Eligibility for other insurance programs - Incomplete or missing documentation - Not meeting medical necessity criteria You may be able to reapply if your circumstances change, or your healthcare provider may be able to help identify alternative assistance programs or treatment options. ## Reauthorization and Renewal You can renew your enrollment each year for as long as you continue to qualify. Your healthcare provider can help you with the renewal process. For Medicare Part D patients, you will need to reauthorize at the beginning of each benefit year. ## Important Reminders - The Novo Nordisk PAP is completely free—there are no registration fees or monthly charges - No one affiliated with Novo Nordisk will ever ask you for payment - All requests are subject to product availability and eligibility verification - Novo Nordisk reserves the right to modify or cancel this program at any time without notice - Ziltivekimab is investigational and may have limited availability ## Contact Information - **Specialty Pharmacy (Delivery & Refills):** 1-800-488-5908 - **Website:** www.novocare.com - **Healthcare Provider Support:** Available through NovoCare ## Disclaimer This guide provides general information about the Novo Nordisk Patient Assistance Program based on current program guidelines. Program eligibility, requirements, and benefits may change at any time. For the most current and accurate information, visit www.novocare.com or contact the program directly. This information is not medical advice. Always consult with your healthcare provider about your treatment options and eligibility for assistance programs. Ziltivekimab is an investigational medication and may not be available outside of clinical trials.

Program information last verified: March 30, 2026